Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients - Concepedia

Concepedia

Publication | Open Access

Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients

DOI Full Paper Access

66

Citations

21

References

2005

Year

Richard P. Wenzel, A. Del Favero, C C Kibbler, Thomas R. Rogers, Coleman Rotstein, Josephine Mauskopf, Stephen Morris, Haran T. Schlamm, Peter F. Troke, A Marciniak

Journal of Antimicrobial Chemotherapy

Abstract

Incremental cost-effectiveness analysis indicated the dominance of voriconazole because of both lower costs and greater efficacy.

References

	Year	Citations

Page 1